Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2

Niclas Roxhed (), Annika Bendes, Matilda Dale, Cecilia Mattsson, Leo Hanke, Tea Dodig-Crnković, Murray Christian, Birthe Meineke, Simon Elsässer, Juni Andréll, Sebastian Havervall, Charlotte Thålin, Carina Eklund, Joakim Dillner, Olof Beck, Cecilia E. Thomas, Gerald McInerney, Mun-Gwan Hong, Ben Murrell, Claudia Fredolini and Jochen M. Schwenk ()
Additional contact information
Niclas Roxhed: KTH Royal Institute of Technology
Annika Bendes: KTH Royal Institute of Technology
Matilda Dale: KTH Royal Institute of Technology
Cecilia Mattsson: KTH Royal Institute of Technology
Leo Hanke: Karolinska Institutet
Tea Dodig-Crnković: KTH Royal Institute of Technology
Murray Christian: Karolinska Institutet
Birthe Meineke: Division of Genome Biology
Simon Elsässer: Division of Genome Biology
Juni Andréll: Stockholm University
Sebastian Havervall: Danderyd Hospital
Charlotte Thålin: Danderyd Hospital
Carina Eklund: Karolinska University Hospital
Joakim Dillner: Karolinska University Hospital
Olof Beck: Karolinska Institutet
Cecilia E. Thomas: KTH Royal Institute of Technology
Gerald McInerney: Karolinska Institutet
Mun-Gwan Hong: KTH Royal Institute of Technology
Ben Murrell: Karolinska Institutet
Claudia Fredolini: KTH Royal Institute of Technology
Jochen M. Schwenk: KTH Royal Institute of Technology

Nature Communications, 2021, vol. 12, issue 1, 1-9

Abstract: Abstract Serological testing is essential to curb the consequences of the COVID-19 pandemic. However, most assays are still limited to single analytes and samples collected within healthcare. Thus, we establish a multianalyte and multiplexed approach to reliably profile IgG and IgM levels against several versions of SARS-CoV-2 proteins (S, RBD, N) in home-sampled dried blood spots (DBS). We analyse DBS collected during spring of 2020 from 878 random and undiagnosed individuals from the population in Stockholm, Sweden, and use classification approaches to estimate an accumulated seroprevalence of 12.5% (95% CI: 10.3%–14.7%). This includes 5.4% of the samples being IgG+IgM+ against several SARS-CoV-2 proteins, as well as 2.1% being IgG−IgM+ and 5.0% being IgG+IgM− for the virus’ S protein. Subjects classified as IgG+ for several SARS-CoV-2 proteins report influenza-like symptoms more frequently than those being IgG+ for only the S protein (OR = 6.1; p

Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-23893-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-23893-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-23893-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().